TY - JOUR
T1 - (S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology
AU - Moutal, Aubin
AU - Chew, Lindsey A.
AU - Yang, Xiaofang
AU - Wang, Yue
AU - Yeon, Seul Ki
AU - Telemi, Edwin
AU - Meroueh, Seeneen
AU - Park, Ki Duk
AU - Shrinivasan, Raghuraman
AU - Gilbraith, Kerry B.
AU - Qu, Chaoling
AU - Xie, Jennifer Y.
AU - Patwardhan, Amol
AU - Vanderah, Todd W.
AU - Khanna, May
AU - Porreca, Frank
AU - Khanna, Rajesh
N1 - Funding Information:
This work was supported by a Career Development Award from the Arizona Health Science Center to M. Khanna, a National Scientist Development grant SDG5280023 from the American Heart Association and a Neurofibromatosis New Investigator Award NF1000099 from the Department of Defense Congressionally Directed Military Medical Research and Development Program to R. Khanna. This work was also partially funded by the Children's Tumor Foundation NF1 Synodos grant (ID 2015-04- 009A) to R. Khanna. A. Moutal was partially supported by a Young InvestigatorAward fromtheChildren's Tumor Foundation. L. A. Chew was partially supported by the Flinn Scholarship, and grants from the University of Arizona's Undergraduate Biology Research Program, the Undergraduate Honors College, and the Neuroscience and Cognitive Science Undergraduate fund. E. Telemi was partially supported by the Medical Student Research Program, funded a T35 from the National Institutes of Health.
Publisher Copyright:
© 2016 International Association for the Study of Pain.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Chronic pain affects the life of millions of people. Current treatments have deleterious side effects. We have advanced a strategy for targeting protein interactions which regulate the N-type voltage-gated calcium (CaV2.2) channel as an alternative to direct channel block. Peptides uncoupling CaV2.2 interactions with the axonal collapsin response mediator protein 2 (CRMP2) were antinociceptive without effects on memory, depression, and reward/addiction. A search for small molecules that could recapitulate uncoupling of the CaV2.2-CRMP2 interaction identified (S)-lacosamide [(S)-LCM], the inactive enantiomer of the Food and Drug Administration-approved antiepileptic drug (R)-lacosamide [(R)-LCM, Vimpat]. We show that (S)-LCM, but not (R)-LCM, inhibits CRMP2 phosphorylation by cyclin dependent kinase 5, a step necessary for driving CaV2.2 activity, in sensory neurons. (S)-lacosamide inhibited depolarization-induced Ca 2+ influx with a low micromolar IC 50. Voltage-clamp electrophysiology experiments demonstrated a commensurate reduction in Ca 2+ currents in sensory neurons after an acute application of (S)-LCM. Using constellation pharmacology, a recently described high content phenotypic screening platform for functional fingerprinting of neurons that uses subtype-selective pharmacological agents to elucidate cell-specific combinations (constellations) of key signaling proteins that define specific cell types, we investigated if (S)-LCM preferentially acts on certain types of neurons. (S)-lacosamide decreased the dorsal root ganglion neurons responding to mustard oil, and increased the number of cells responding to menthol. Finally, (S)-LCM reversed thermal hypersensitivity and mechanical allodynia in a model of postoperative pain, and 2 models of neuropathic pain. Thus, using (S)-LCM to inhibit CRMP2 phosphorylation is a novel and efficient strategy to treat pain, which works by targeting specific sensory neuron populations.
AB - Chronic pain affects the life of millions of people. Current treatments have deleterious side effects. We have advanced a strategy for targeting protein interactions which regulate the N-type voltage-gated calcium (CaV2.2) channel as an alternative to direct channel block. Peptides uncoupling CaV2.2 interactions with the axonal collapsin response mediator protein 2 (CRMP2) were antinociceptive without effects on memory, depression, and reward/addiction. A search for small molecules that could recapitulate uncoupling of the CaV2.2-CRMP2 interaction identified (S)-lacosamide [(S)-LCM], the inactive enantiomer of the Food and Drug Administration-approved antiepileptic drug (R)-lacosamide [(R)-LCM, Vimpat]. We show that (S)-LCM, but not (R)-LCM, inhibits CRMP2 phosphorylation by cyclin dependent kinase 5, a step necessary for driving CaV2.2 activity, in sensory neurons. (S)-lacosamide inhibited depolarization-induced Ca 2+ influx with a low micromolar IC 50. Voltage-clamp electrophysiology experiments demonstrated a commensurate reduction in Ca 2+ currents in sensory neurons after an acute application of (S)-LCM. Using constellation pharmacology, a recently described high content phenotypic screening platform for functional fingerprinting of neurons that uses subtype-selective pharmacological agents to elucidate cell-specific combinations (constellations) of key signaling proteins that define specific cell types, we investigated if (S)-LCM preferentially acts on certain types of neurons. (S)-lacosamide decreased the dorsal root ganglion neurons responding to mustard oil, and increased the number of cells responding to menthol. Finally, (S)-LCM reversed thermal hypersensitivity and mechanical allodynia in a model of postoperative pain, and 2 models of neuropathic pain. Thus, using (S)-LCM to inhibit CRMP2 phosphorylation is a novel and efficient strategy to treat pain, which works by targeting specific sensory neuron populations.
KW - (S)-lacosamide
KW - CRMP2
KW - CaV2.2
KW - Calcium imaging
KW - Constellation pharmacology
KW - Neuropathic pain
KW - Postoperative pain
UR - http://www.scopus.com/inward/record.url?scp=84976370483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976370483&partnerID=8YFLogxK
U2 - 10.1097/j.pain.0000000000000555
DO - 10.1097/j.pain.0000000000000555
M3 - Article
C2 - 26967696
AN - SCOPUS:84976370483
SN - 0304-3959
VL - 157
SP - 1448
EP - 1463
JO - Pain
JF - Pain
IS - 7
ER -